IL-6 deficiency leads to reduced metallothionein-I+II expression and increased oxidative stress in the brain stem after 6-aminonicotinamide treatment

Exp Neurol. 2000 May;163(1):72-84. doi: 10.1006/exnr.2000.7383.

Abstract

We examined the effects of interleukin-6 (IL-6) deficiency on brain inflammation and the accompanying bone marrow (BM) leukopoiesis and spleen immune reaction after systemic administration of a niacin antagonist, 6-aminonicotinamide (6-AN), which causes both astroglial degeneration/cell death in brain stem gray matter areas and BM toxicity. In both normal and genetically IL-6-deficient mice (IL-6 knockout (IL-6KO) mice), the extent of astroglial degeneration/cell death in the brain stem was similar as determined from disappearance of GFAP immunoreactivity. In 6-AN-injected normal mice reactive astrocytosis encircled gray matter areas containing astroglial degeneration/cell death, which were infiltrated by several macrophages and some T-lymphocytes. Reactive astrocytes and a few macrophages increased significantly the antioxidants metallothionein-I+II (MT-I+II) and moderately the MT-III isoform. In 6-AN-injected IL-6KO mice reactive astrocytosis and recruitment of macrophages and T-lymphocytes were clearly reduced, as were BM leukopoiesis and spleen immune reaction. Expression of MT-I+II was significantly reduced while MT-III was increased. Oxidative stress, as determined by measuring nitrated tyrosine and malondialdehyde, was increased by 6-AN to a greater extent in IL-6KO mice. The blood-brain barrier to albumin was only disrupted in 6-AN-injected normal mice, which likely is due to the substantial migration of blood-derived inflammatory cells into the CNS. The present results demonstrate that inflammation in CNS is clearly reduced during IL-6 deficiency and this effect is likely due to significant inhibition of BM leukopoiesis. We also show that IL-6 deficiency reduces the levels of neuroprotective antioxidants MT-I+II followed by an increased oxidative stress during CNS inflammation.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • 6-Aminonicotinamide / metabolism*
  • 6-Aminonicotinamide / pharmacology
  • Animals
  • Antigens, Differentiation / metabolism
  • Astrocytes / drug effects
  • Astrocytes / metabolism
  • Astrocytes / pathology
  • Blood-Brain Barrier / drug effects
  • Blood-Brain Barrier / genetics
  • Blood-Brain Barrier / immunology
  • Bone Marrow Cells / drug effects
  • Bone Marrow Cells / metabolism
  • Brain Stem / drug effects
  • Brain Stem / immunology
  • Brain Stem / metabolism*
  • Brain Stem / pathology
  • Encephalitis / genetics
  • Encephalitis / immunology
  • Encephalitis / metabolism
  • Glial Fibrillary Acidic Protein / biosynthesis
  • Hematopoiesis / drug effects
  • Hematopoiesis / immunology
  • Immunohistochemistry
  • Interleukin-6 / deficiency*
  • Interleukin-6 / genetics
  • Macrophages / drug effects
  • Macrophages / metabolism
  • Malondialdehyde / immunology
  • Malondialdehyde / metabolism
  • Metallothionein / biosynthesis*
  • Metallothionein 3
  • Mice
  • Mice, Inbred C57BL
  • Mice, Knockout
  • Microglia / cytology
  • Microglia / drug effects
  • Microglia / metabolism
  • Nerve Tissue Proteins / biosynthesis
  • Oxidative Stress / drug effects
  • Oxidative Stress / genetics
  • Oxidative Stress / immunology*
  • Protein Isoforms / biosynthesis
  • Serum Albumin / metabolism
  • T-Lymphocytes / drug effects
  • T-Lymphocytes / metabolism
  • Tyrosine / analogs & derivatives
  • Tyrosine / immunology
  • Tyrosine / metabolism

Substances

  • Antigens, Differentiation
  • Glial Fibrillary Acidic Protein
  • Interleukin-6
  • Metallothionein 3
  • Nerve Tissue Proteins
  • Protein Isoforms
  • Serum Albumin
  • 6-Aminonicotinamide
  • 3-nitrotyrosine
  • Tyrosine
  • Malondialdehyde
  • Metallothionein